A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center One hundred twenty-two participants completed the survey. The majority ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Of all the health conditions facing men as they get older, there is no doubt that prostate cancer is the most widely ...

Drugmaker Novartis’ Super Bowl ad explained that prostate cancer screening starts with a simple blood test, aiming to dispel fear of an exam for a treatable cancer.